Hexanucleotide-repeat expansions in the C9ORF72 gene are the most common cause of amyotrophic lateral sclerosis and frontotemporal dementia (c9ALS/FTD). The nucleotide-repeat expansions are translated into dipeptide-repeat (DPR) proteins, which are aggregation prone and may contribute to neurodegeneration. We used the CRISPR-Cas9 system to perform genome-wide gene-knockout screens for suppressors and enhancers of C9ORF72 DPR toxicity in human cells. We validated hits by performing secondary CRISPR-Cas9 screens in primary mouse neurons. We uncovered potent modifiers of DPR toxicity whose gene products function in nucleocytoplasmic transport, the endoplasmic reticulum (ER), proteasome, RNA-processing pathways, and chromatin modification. One modifier, TMX2, modulated the ER-stress signature elicited by C9ORF72 DPRs in neurons and improved survival of human induced motor neurons from patients with C9ORF72 ALS. Together, our results demonstrate the promise of CRISPR-Cas9 screens in defining mechanisms of neurodegenerative diseases.
A myotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are devastating human neurodegenerative disorders. ALS is associated with progressive loss of motor neurons from the brain and spinal cord, thus leading to muscle weakness, paralysis, and ultimately death, usually 2-5 years after symptom onset 1 . FTD, the second most common cause of dementia in patients younger than 65 years of age, is caused by the degeneration of neurons from the frontal and temporal lobes of the brain and is associated with a range of cognitive and behavioral symptoms, including changes in personality. There is an emerging appreciation for clinical overlap between ALS and FTD, along with evidence of FTD symptoms in patients with ALS and of motor neuron signs in patients with FTD 2 . The two disorders are also connected by pathology and genetics. Aggregates of the RNA-binding protein TDP-43 accumulate in neurons in nearly all ALS cases and almost half of FTD cases 3 , and mutations in several genes can cause ALS, FTD, or even both (ALS/FTD) 4 . Mutations in one such gene, C9ORF72, are the most common cause of ALS and FTD 5, 6 .
The ALS-and FTD-causing mutation in the C9ORF72 gene is a massively expanded hexanucleotide repeat (GGGGCC) 5, 6 , which produces sense and antisense RNA foci 5 and is translated into aggregation-prone DPR proteins through an unconventional form of AUG-independent translation (also called RAN translation) [7] [8] [9] [10] . Studies in flies and human cells have suggested that DPRs may be the main drivers of neuronal toxicity [11] [12] [13] . The arginine-rich DPRs glycine-arginine (GR) and proline-arginine (PR) are particularly toxic in experimental models 11, [13] [14] [15] [16] . Synthetic PR or GR DPRs added exogenously to the culture medium are rapidly transported to the nucleus and subsequently cause disruptions in RNA splicing-including in the canonical splicing and biogenesis of ribosomal RNA-and induce cell death in a dose-dependent manner 14 . Subsequent studies have provided evidence through coimmunoprecipitation and mass spectrometry that these DPRs preferentially bind proteins with low-complexity domains, including RNA-binding proteins [17] [18] [19] , ribosomal proteins, and translation-elongation factors 20, 21 , as well as components of the nuclear-pore complex 22 .
Genetic screens in simple experimental model organisms such as yeast, flies, and worms have empowered the discovery of fundamental biological processes including mechanisms of human disease 23 . For example, we and others have used genetic screens in model systems to identify modifiers of toxicity elicited by aggregation-prone neurodegenerative-disease proteins, such as TDP-43, FUS, amyloid-β , α -synuclein, mutant huntingtin, and C9ORF72 DPRs 15, 16, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . Underscoring the utility of these simple model systems, some of the modifier genes from the genetic screens have been validated in mouse models and even connected to human disease through genetics and neuropathology [35] [36] [37] .
Although model systems have been powerful experimental tools for the study of human neurodegenerative disease mechanisms, it would be empowering to have access to the human genome to perform similar modifier screens in human cells. Recent technological advances in CRISPR-Cas9 genome editing have expanded the scope and reliability of genome-wide genetic deletion screens to the human genome by using high-complexity single-guide RNA (sgRNA) libraries [38] [39] [40] [41] [42] . Here, we used the CRISPR-Cas9 system to perform comprehensive genome-wide knockout (KO) screens in human cells and targeted screens in mouse primary neurons to identify genetic modifiers of C9ORF72 DPR toxicity.
CRISPR-Cas9 screens in human cells and primary neurons identify modifiers of C9ORF72 dipeptiderepeat-protein toxicity
effect (protective, sensitizing, or neutral) of each sgRNA in a pooled population of KO cells. That is, sgRNAs that protected cells from DPR toxicity were enriched, and those that sensitized cells were depleted from the pooled population of cells. To identify both protective and sensitizing gene KOs in the same screen, we treated the pooled population of cells with a DPR dose sufficient to kill 50% of cells and repeated this treatment four times over the course of the screen to amplify the selection. We performed separate screens for modifiers of PR 20 and GR 20 toxicity, and repeated each screen two independent times.
To detect statistically significant suppressors and enhancers of DPR toxicity, we used the Cas9 high-throughput maximum-likelihood estimator (casTLE) algorithm as previously described 45 . With a false discovery rate (FDR) cutoff of 10%, the screens identified 215 genetic modifiers of PR 20 toxicity and 387 genetic modifiers of GR 20 toxicity ( Fig. 1f, Supplementary Fig. 2a-c and Supplementary  Table 1 ). Results from the PR 20 and the GR 20 screen were well correlated (R 2 = 0.61), thus suggesting similar mechanisms of toxicity ( Fig. 1g ). We validated individual KO K562 lines by performing competitive-growth assays with PR 20 treatment. We tested five *** *** ** ***
K562 cells expressing Cas9
Lentiviral sgRNA genome-wide-KO library (10 sgRNAs/gene + 10,000 negative controls) or GR 20 (c)) were added to the culture medium of K562 cells; dose-dependent cytotoxicity was measured through flow cytometry (n = 3 independent cell culture experiments; error bars, s.d.). b,d, DPRs were visualized by immunocytochemistry in cells treated with PR 20 (b) or GR 20 (d) (blue, DAPI nuclear stain; green, anti-FLAG; scale bars, 10 µ m). e, Pooled CRISPR-Cas9 screening paradigm. K562 cells expressing Cas9 were infected with a lentiviral sgRNA library (ten sgRNAs per gene), the population was split, and half the cells were treated with PR 20 or GR 20 for four pulses (at concentrations sufficient to kill 50% of cells in each pulse); the resulting populations were subjected to deep sequencing and analysis. Screens were repeated two independent times for each DPR. f, Volcano plot for genes in the GR 20 screen. Blue, all genes conferring resistance to GR 20 when knocked out (10% FDR); red, all genes conferring sensitivity to GR 20 when knocked out (10% FDR). g, Correlation of signed confidence scores of significant hits between GR 20 and PR 20 screens (R 2 = 0.61). h, Validation of hits, using independently generated single-gene-KO K562 lines in coculture competitive-growth assays. Equal numbers of KO (GFP + ) and WT control cells (GFP -) were cocultured in equal starting numbers and treated with PR 20 (10 µ M). The abundance of KO cells (GFP + ) was quantified by flow cytometry 48 h after PR 20 treatment and compared against the untreated population (n = 3 independent cell culture experiments, two-tailed t test; ***P < 0.001, **P < 0.01; error bars, s.d.) Each gene was validated with two distinct sgRNAs.
Sequencing and sgRNA distribution analysis
genes from the primary screen (two guides per gene) and all five genes validated in these assays ( Fig. 1h ). Furthermore, to assess the specificity of our screens, we compared the hits from our genomewide screens against the hits from a similar screen performed for ricin toxicity, which used the same cell line, sgRNA library, and method of exogenous application of a toxic protein 44 . We found zero correlation between the hits in the two screens (R 2 = 0), thus indicating that we uncovered specific genetic modifiers rather than nonspecific genes involved in general peptide-mediated toxicity ( Supplementary Fig. 2d ). Among the hits from these KO screens were genes encoding some of the same nuclear-import and nuclear-export factors discovered in DPR modifier screens in model organisms 15, 16, 46, 47 , such as XPO6 and IPO11 (Fig. 2) , thus suggesting that the same mechanisms are important in mammalian cells. We also identified many novel genetic modifiers of PR and GR toxicity, including genes encoding RNA-binding proteins that have been shown to physically interact with PR and GR 17 , such as NONO and HNRNPF. We also identified genes involved in RNA splicing, such as SPEN and PQBP1, a process previously observed to be dysregulated in the brains of patients with c9ALS/FTD 48 and to be dramatically disrupted in human cell lines treated with DPRs 14 . In addition to these previously implicated genes, some of the strongest hits in the screen were genes encoding ER-resident proteins (such as TMX2 and CANX) and almost all members of the ER-membrane protein complex (the EMC complex), which is upregulated by ER stress and is thought to be involved in ER-associated degradation [49] [50] [51] . Genes encoding proteasome subunits, as well as chromatin modifiers and transcriptional regulators, such as those involved in histone lysine methylation (KDM6A, KMT2D, KMT2A, and SETD1B), were also significant genetic modifiers of PR and GR toxicity ( Fig. 2 ).
CRISPR-Cas9 screens in primary mouse neurons.
To evaluate the roles of the genetic modifiers identified in our human genomewide screens in a more disease-relevant context, we next designed a strategy to conduct pooled CRISPR-Cas9 screens in mouse primary cortical neurons. In these primary neurons, similarly to human cell lines, synthetic PR 20 dipeptides were toxic in a dose-dependent manner ( Fig. 3a ). However, to better model the endogenous production of DPRs, as occurs in the brain in ALS/FTD, we also used a lentiviral construct for expression of codon-optimized PR 50 driven by the neural-specific synapsin promoter 52 . When expressed in primary neurons, PR 50 localized to nuclear puncta and elicited neurotoxicity in a time-dependent manner ( Fig. 3b and Supplementary  Fig. 3a ). We constructed a custom lentiviral sgRNA library to test the top ~200 genes (5% FDR) that were modifiers of PR 20 toxicity in the genome-wide CRISPR screens. The custom library contained ten sgRNAs targeting each mouse gene and ~1,000 negative-control sgRNAs. Using primary-neuron cultures isolated from mice constitutively expressing Cas9 (ref. 53 ), we used immunoblotting to confirm efficient knockdown of proteins encoded by target genes after transduction with sgRNAs from this library, after at least 10 d in culture ( Supplementary Fig. 4a-c) .
We performed the primary-neuron CRISPR screens in two ways: either lentiviral expression of PR 50 in neurons or treatment of neurons with exogenous synthetic PR 20 (Fig. 3c ). In this way, we were able to simultaneously validate hits from the genome-wide screens and distinguish the genes responsible for the uptake and spread of the DPRs throughout the cell from those responsible for mediating the toxic effects after entry into the cell. We performed these targeted CRISPR KO screens such that there was a ~90% decrease in viability after one round of selection. Given the stringency of this screen, together with the nondividing nature of these neurons, we expected only genetic modifiers with the strongest effects to be enriched. We harvested the surviving neurons and used deep sequencing to assess sgRNA enrichment relative to that in the control populations ( Fig. 3c ). We identified 13 modifier genes in the synthetic PR 20 screen and 17 genes in the lentiviral PR 50 expression screen (determined by having a nonzero estimated effect with a 95% credible interval) ( Fig. 3d ,e, Supplementary Fig. 4d and Supplementary Table 2 ). The genes that validated in these neuronal cultures showed strong specificity to the method of PR delivery to the neurons. We further validated the two strongest modifier genes from these neuronal screens in an independent primary-neuron culture model of DPR toxicity, using mouse dorsal root ganglion neurons. KO of either Rab7 or Tmx2 protected against PR toxicity in these primary neurons ( Fig. 4a-d ).
RAB7A and intracellular transport of PR 20 . A top hit in the screen for modifiers of synthetic PR 20 -induced toxicity was the endolysosomal trafficking gene RAB7A (Fig. 3d ). We hypothesized that the endosomal trafficking pathway is necessary for the intracellular transport of exogenously applied PR 20 . We tested this hypothesis in wild-type (WT) and RAB7A-knockdown HeLa cells by using immunocytochemistry and found altered subcellular localization of PR 20 ( Supplementary Fig. 3b ) indicating that endolysosomal trafficking is important for the localization and subsequent toxicity of synthetic PR 20 . We used the CRISPR-interference system to Fig. 1b,d and Supplementary Fig. 1 ). However, at n refers to independent cell culture experiments two-tailed t test; ****P < 0.0001, ***P < 0.001, **P < 0.01; error bars, s.e.m.). c, CRISPR-Cas9 screening paradigm in primary mouse neuron cultures. Cortical neurons were plated and infected with sgRNA libraries (~200 genes passing 5% FDR cutoff from genome-wide PR screen with ten sgRNAs per gene plus ~1,000 negative-control sgRNAs). Four independent screening conditions were conducted, each in replicate: synthetic PR 20 -treated neurons (1.5 μ M, overnight), untreated neurons, lentiviral expression of PR 50 (5 d) , and lentiviral expression of GFP (5 d) as a control. The abundance of sgRNAs in surviving cells was measured by sgRNA deep sequencing. PR 50 localized to the nuclei in cultured neurons (blue, DAPI; red, anti-FLAG (PR 50 ); green, anti-MAP2). d,e, Volcano plots of effect and confidence scores of all genes for each screen. Effect and confidence scores were calculated with casTLE 45 . The effect score is a gene-level summary of how protective or sensitizing the KO is; the confidence score is a log-likelihood ratio describing the significance of the effect. Genes were designated hits if their 95% credible intervals derived from casTLE did not contain zero; 13 genes in the synthetic PR 20 screen (d) and 17 genes in the lentiviral PR 50 screen (e) passed these criteria ( Supplementary Fig. 4d and Supplementary Table 2 ). this same early time point in RAB7A-knockdown cells (denoted Rab7-i.1 cells), PR 20 accumulated in numerous puncta speckled throughout the cytosol, a result indicative of an early endomembrane compartment ( Supplementary Fig. 3b ). Given that cell-to-cell spread of DPRs may be relevant to disease 54, 55 , understanding mechanisms of DPR cellular entry and trafficking may inform strategies to block this process.
C9ORF72 DPRs induce an ER-stress response. In contrast to the results of the screen with synthetic PR 20 , none of the trafficking genes present in the sublibrary were hits in the screen in which neuronal toxicity was induced by lentivirus-mediated PR 50 expression. In this screen, the strongest genetic modifiers were genes encoding proteins predominantly localized to the nucleus and ER; a top protective KO was the poorly characterized ER-resident transmembrane thioredoxin protein Tmx2 ( Fig. 3e ). Because this hit is implicated in ER function, our results suggested that DPR accumulation might induce an ER-stress response. To test this hypothesis, we performed RNA sequencing (RNA-seq) on primary-neuron cultures transduced with a lentivirus for expression of either PR 50 or GFP ( Fig. 5a ). After 4 d of PR 50 expression, 126 genes were significantly upregulated, and 133 genes were significantly downregulated (DESeq2, adjusted P value < 0.05; Fig. 5b , Supplementary Fig. 5 and Supplementary Table 3 ). A significantly enriched Gene Ontology (GO) category among upregulated genes was 'apoptotic signaling pathway in response to endoplasmic reticulum stress' (GO 0070059) ( Fig. 5c ). Genes in this enriched ontology category included Atf4, Bbc3 (also known as Puma), Chac1, Bax, and the ER Ca 2+ -channel gene Itpr1, for which loss-of-function variants have been shown to cause spinocerebellar ataxia 56 (Fig. 5d ). Other notable enriched GO categories among these differentially expressed genes included 'neuronal apoptosis' , 'ion homeostasis' , 'ribonucleoprotein' , 'translation' , and 'DNA repair' . From these RNA-seq results, we confirmed a time-dependent induction of ER-stress-related genes by using PR 50 expression and quantitative reverse-transcription PCR (qRT-PCR) (Fig. 5e ). The Ire1 stress sensor of the unfolded-protein response was not activated by PR 50 expression in neurons, as determined by the levels of spliced Xbp1 mRNA (Fig. 5h ). These data were consistent with activation of the integrated stress response, which converges on eIF2 and the upregulation of the transcription factor Atf4 (ref. 57 ). To confirm that these ER-stress responses are conserved in other models of DPR toxicity, we performed RNA-seq on primary mouse neurons as well as human K562 cells, each treated with synthetic PR 20 . ATF4 and related ER-stress-response genes were also induced in each of these models ( Fig. 5f, Supplementary Fig. 6 and Supplementary Table 3 ). Finally, in addition to observing the genetic signatures of ER stress, we also used a pharmacological approach to test the importance of this pathway in response to PR 20 . The small molecule ISRIB, a potent inhibitor of the cellular response to ER stress 58 , inhibits ATF4 induction by modulating eIF2α signaling during the integrated stress response 59 . Pretreatment of K562 cells with 15 nM ISRIB mitigated PR 20 toxicity ( Fig. 5g ), thus providing further evidence of a role of ER stress in DPR-mediated toxicity. Future experiments will be required to validate ISRIB's efficacy in primary neurons and animal models of C9ORF72 DPR toxicity.
Tmx2 modifies the C9ORF72 DPR-induced ER-stress response. Several lines of evidence have suggested a potential role for ER stress in C9ORF72 pathogenesis. Transcriptomic analysis of C9ORF72-mutant ALS brain tissue has revealed an upregulation of genes involved in the unfolded-protein response and ER stress 48 . A specific PERK-ATF4-mediated ER-stress response has been reported in a separate study of brain tissue from patients with c9ALS/FTD compared with ALS 60 . Additionally, ER stress and disruptions to ER Ca 2+ homeostasis have been observed in induced pluripotent stem cell (iPSC)-derived motor neurons from patients with c9ALS/FTD 61 . Given that a main transcriptional stress response to endogenous and exogenous DPR treatment was the ER stress response, we chose to further investigate TMX2, a gene encoding a poorly characterized ER-resident protein that was one of the strongest protective hits in both the PR and GR genome-wide CRISPR screens in K562 cells and in the targeted primary-neuron screen expressing PR 50 . We first confirmed that the sgRNAs targeting TMX2 effectively knocked out the gene in K562 cells and primary neurons cultured from Cas9-expressing mice ( Fig. 6a and Supplementary Fig. 7a ). The decrease in TMX2 levels was sufficient to markedly suppress C9ORF72 DPR toxicity both in K562 cells ( Supplementary Fig. 7b ) and in primary mouse cortical neurons (Fig. 6b,c) .
TMX2 is an ER-resident transmembrane thioredoxin protein that may be enriched at the mitochondrial-associated membrane of the ER 62 . It is a member of the protein disulfide isomerase family, but whether it is catalytically active remains unclear, given that it contains an SXXC motif instead of the canonical CXXC motif necessary for the oxidoreductase activity used to catalyze the formation or rearrangement of disulfide bonds 63 . To define the mechanism by which decreased Tmx2 mitigates DPR toxicity, we performed RNA-seq Ctl. lenti on primary Cas9 + neurons infected with control sgRNAs (Safe) or sgRNAs targeting Tmx2, with or without PR 50 expression ( Fig. 6d,e and Supplementary Fig. 7c-h) . After PR 50 expression, Tmx2-KO neurons, as compared with primary neurons expressing control sgRNAs, upregulated a distinct set of prosurvival unfolded-proteinresponse-pathway genes and downregulated genes encoding calcium-binding and apoptotic proteins (Fig. 6d,e and Supplementary  Table 3 ). We used qRT-PCR to validate one of the upregulated ER-stress genes observed in the Tmx2-KO neurons after PR 50 expression, Atf3, which has been previously shown to be protective when overexpressed in mouse models of ALS 64 and neuronal models of excitotoxicity 65 (Fig. 6f) . These results suggest that decreased Tmx2 may be protective by modulating the ER-stress response elicited by the DPRs. Indeed, upregulation of Atf3 alone was sufficient to protect primary cortical neurons from PR toxicity ( Fig. 6g-i) .
Lowering TMX2 and survival of C9-ALS motor neurons. Given the strong protective effect of Tmx2 knockdown on PR-mediated toxicity in rodent primary neurons, we tested whether lowering TMX2 levels might modify the survival phenotypes in neuronal cells from patients with ALS harboring endogenous C9orf72 GGGGCC expansions. We generated induced motor neurons (iMNs) from iPSCs from patients with C9orf72 ALS and unaffected individuals by using transcription-factor-mediated lineage conversion, as previously described 13, 66 . These C9-ALS patient-derived iMNs, as compared with control iMNs, showed poorer survival after glutamate addition ( Fig. 7, Supplementary Fig. 8 and ref. 13 ). Using a seven factor (7F) differentiation method to generate iMNs, we tested two independent shRNAs targeting TMX2 and found that both shR-NAs, as compared with control shRNAs, significantly increased the proportion of surviving C9orf72 iMNs in two independent C9-ALS lines (Fig. 7a,b ) but did not increase the proportion of surviving control iMNs ( Supplementary Fig. 8 ). We repeated this experiment by using a different differentiation method (Dox-NIL) to generate iMNs and found a similar protective effect of decreased TMX2 in C9-ALS but not control iMNs, though there was a degree of variability in the extent of rescue among patient lines with this differentiation method ( Supplementary Fig. 9 ). Further studies will be required to assess the effects of TMX2 on C9orf72-related pathologies in additional patient cell lines and ALS models, but these results suggest that our screening strategy may be useful to identify potent modifiers of ALS-related phenotypes.
Discussion
Here, we used comprehensive CRISPR-Cas9 KO screens in human cells with further validation screens in primary neurons to discover modifiers of C9ORF72 DPR toxicity. We identified nucleocytoplasmic-transport machinery, confirming the results from previous studies in model organisms 15, 16 , and also identified new genes that suggest that ER function and ER stress are important in c9FTD/ALS pathogenesis. The gene KOs that mitigated toxicity, such as TMX2, may serve as future therapeutic targets. Notably, decreased TMX2 expression conferred protection from PR toxicity across multiple cellular assays, including in primary rodent neurons. There are five distinct DPRs produced from the C9ORF72 GGGGCC-repeat expansion: glycine-alanine (GA), glycinearginine (GR), glycine-proline (GP), proline-alanine (PA), and proline-arginine (PR) (GP is produced from both the sense and antisense transcript). Our studies here focused on two of these DPRs, GR and PR. The relative contribution of each DPR to neurodegeneration and the potential for synergistic effects among multiple DPRs remains to be defined. Although the evidence from model systems for a role of DPRs in neurodegeneration is compelling, there are some caveats. These studies, including ours, used either exogenous addition of synthetic DPRs to cells or high levels of transgenic expression of specific DPRs, which might not accurately reflect the physiological levels of DPRs. Moreover, studies of c9ALS/FTD neuropathology have also produced results that seem to not support a role of DPRs as the drivers of neurodegeneration. The abundance and localization of DPR pathology does not appear to correlate with neurodegeneration and clinical phenotypes [67] [68] [69] [70] [71] . Finally, GA and GP DPRs seem to be the most abundant but are the least toxic in model systems 11, 15, 16 , and the most toxic DPR, PR, is extremely rare 70 . One possible explanation for this apparent disconnect is that the most toxic DPRs (for example, GR and PR) do not accumulate to high enough levels (because they are so toxic) before causing neuron death, whereas the others (for example, GA and GP) can accumulate to higher levels because they are more benign 72 .
Beyond the DPRs, RNA foci from the sense (GGGGCC) and antisense (GGCCCC) repeat transcripts, as well as loss of function of the C9ORF72 gene could also contribute to disease. These different mechanisms may also interact with one another. For example, loss of C9ORF72 function may make neurons or glia more vulnerable to the RNA foci or DPRs. Additionally, our work here provides evidence that DPRs can elicit an ER-stress response, and recent work shows that ER stress can increase RAN translation 73, 74 , thus suggesting the potential for a feed-forward loop. It will be important to define the relative contributions of each of these facets of C9ORF72 pathology (loss of function, RNA foci, and DPRs) to disease so that effective therapeutic strategies can be developed. If the DPRs are indeed key contributors to disease, our work here identifies novel suppressors of DPR toxicity that may be potential therapeutic targets.
Beyond the types of CRISPR KO screens used here, the CRISPR-Cas9 system has been adapted for use in other types of genetic screens. Through use of Cas9 with a deactivated nuclease (dCas9), which is unable to generate double-strand breaks, specific genomic regions can be targeted for transcriptional control 75, 76 . Fusing a KRAB effector domain to Cas9 results in transcriptional repression (CRISPR interference) 77 . Alternatively, CRISPR activation uses dCas9 fused with various transcriptional-activation domains, thereby empowering genome-wide transcriptional activation (i.e., overexpression) screens [76] [77] [78] [79] . Thus, the same logic applied to yeast, worm, and fly genetic screens for up-or downregulation of genes can now be achieved in human cells on a genome-wide scale. We anticipate that CRISPR screens in human cells and primary Induced motor neurons were generated from iPSCs with a 7 factor (7F) differentiation system. The survival of HB9-RFP + /shRNA-GFP + iMNs was tracked by imaging after the addition of 10 µ M glutamate to the cultures. All iMN survival experiments were analyzed by log-rank test, and statistical significance was calculated by using the entire survival time course. *P < 0.05, **P < 0.01, ****P < 0.0001 (log-rank tests; survival assays were performed in triplicate with the indicated number of iMNs analyzed for each group, Supplementary Table 4 ).
Methods
Cell culture. K562 cells (ATCC) were cultured in RPMI-1640 (Gibco) medium with 10% FBS (Hyclone), penicillin (10,000 IU/m;), streptomycin (10,000 μ g/ml), and l-glutamine (2 mM). Cells were grown in log phase by maintaining the population at a concentration of 500,000 cells/ml. K562 cells were maintained in a controlled humidified incubator at 37 °C, with 5% CO 2 . Primary mouse cortical neurons were dissociated into single-cell suspensions from E16.5 mouse cortices with a papain dissociation system (Worthington Biochemical Corporation). Neurons were seeded onto poly-l-lysine-coated plates (0.1% (wt/vol)) and grown in Neurobasal medium (Gibco) supplemented with B-27 serum-free supplement (Gibco), GlutaMAX, and penicillin-streptomycin (Gibco) in a humidified incubator at 37 °C, with 5% CO 2 . Half media changes were performed every 4 or 5 d, or as required. For gene-knockout experiments in Cas9 + cortical neurons, lentiviruses encoding sgRNAs expressed from a U6 promoter were transduced on DIV1. Cultures were incubated for at least 10 d with the sgRNAs to obtain adequate knockdown of target-protein levels before further experiments were performed. Mouse experiments were approved by the Stanford Administrative Panel on Animal Care (APLAC).
Dorsal root ganglion cultures. 24-well plates were coated overnight with PDL (100 µ g/ml) and, after a water wash, were coated with laminin (1.33 mg/ml) for at least 3 h. DRGs were dissected from E12.5 mouse embryos and dissociated in 0.05% trypsin-EDTA. Dissociated neurons were plated in Neurobasal medium supplemented with 2% B27, 0.45% d-glucose, 1% GlutaMAX, 100 U/ml penicillin, and 100 U/ml streptomycin. On DIV1, the cultures were fed with fresh Neurobasal/B-27 medium containing 5 µ M 5-fluoro-2′ -deoxyuridine and 5 µ M uridine to inhibit the growth of non-neuronal cells. On DIV1, cells were transduced with lentivirus for expression of sgRNAs targeting a safe genomic region (Safe), TMX2, or Rab7. Cultures were treated with PR at 0.5 µ M on DIV10. For ATP measurement, neuronal cell bodies and proximal axons were removed, and axons were subjected to ATP measurement with Cell Titer Glo (Promega) or Caspase 3/7 Glo (Promega).
Generation of stable RAB7A-knockdown cells. HeLa cells stably expressing dCas9
fused to a KRAB domain were infected with either sgRNAs targeting RAB7A or a negative-control sgRNA. Cells were selected with puromycin (1 μ g/ml) for stable sgRNA expression.
Lentivirus production. HEK293T (ATCC) cells were cultured under standard conditions (DMEM plus 10% FBS plus penicillin-streptomycin) and used to package lentiviral particles according to standard protocols with third-generation packaging plasmids. Lentivirus-containing medium was harvested after 48 h, centrifuged at 300 g for 5 min to remove cellular debris, and concentrated tenfold with Lenti-X concentrator (Clontech) before being added to cell cultures. GFP or PR 50 -FLAG constructs were cloned into a third-generation lentiviral vector for expression of the transgenes under the control of the neuron-specific human synapsin 1 promoter (SYN).
Lentivirus production for iPSC-derived motor neuron experiments. All shRNA and Hb9::RFP-encoding lentiviruses were produced as follows: HEK293T cells were transfected at 80-90% confluency with viral vectors containing the genes of interest and viral packaging plasmids (pPAX2 and VSVG for lentivirus) by using polyethylenimine (PEI) (Sigma-Aldrich). The medium was changed 24 h after transfection. Viruses were harvested at 48 and 72 h after transfection. Viral supernatants were filtered with 0.45-μ M filters and concentrated by incubation with Lenti-X concentrator (Clontech) for 24 h at 4 °C, then centrifugation at 1,500 g at 4 °C for 45 min. The pellets were resuspended in 300 μ l DMEM with 10% FBS and stored at -80 °C.
Immunocytochemistry and antibodies. Cells were grown on poly-l-lysine-coated glass coverslips (0.1% (wt/vol) in standard multiwell cell culture plates and were stained through standard immunocytochemistry techniques. Briefly, cells were fixed with 4% formaldehyde, permeabilized with 0.1% Triton X-100, blocked with 5% normal goat serum, and stained with the following antibodies: mouse monoclonal anti-FLAG (1:1,000, M2 Sigma F1804), mouse monoclonal anti-MAP2A (1:1,000, Millipore MAB378), mouse monoclonal anti-V5 tag (1:500, Thermo Fisher Scientific R960-25), rabbit monoclonal anti-LAMP1 (1:200, clone D2D11, Cell Signaling Technology 9091), or mouse monoclonal anti-NeuN (1:1,000, Millipore MAB377). Coverslips were mounted with Prolong Diamond Antifade Mountant with DAPI (Thermo Fisher Scientific). Images were acquired with either a Leica DMI6000B inverted fluorescence microscope with a 40× oil-immersion objective or a confocal Zeiss LSM710 microscope with a 63× oil-immersion objective. The percentage area of MAP2 immunofluorescence staining was quantified in ImageJ. Images in a stack were thresholded, and the percentage area of the signal for each image was measured.
DRG immunocytochemistry. Neuronal cultures were fixed in 4% (wt/vol) paraformaldehyde/PBS at room temperature for 15 min, then permeabilized with 0.1% Triton X-100/PBS for 30 min. After being blocked for 1 h with 5% bovine serum albumin (BSA)/0.1% Triton X-100/PBS, axons were then stained with anti-Tuj1 (1:2,000, Covance 801201) in blocking buffer at 4 °C overnight. After being washed two times with 0.1% Triton X-100/PBS, axons were labeled with the appropriate Alexa-dye-conjugated secondary antibodies (Life Technologies) for 2 h at room temperature, washed three times with 0.1% Triton-X-100/PBS, and mounted in Fluoromount-G.
Genome-wide CRISPR-Cas9 screens in K562 cells.
The CRISPR/Cas9 deletion library with ten sgRNAs per gene was synthesized, cloned, and infected into Cas9expressing K562 cells, as previously described 44 . Briefly ~300 million K562 cells stably expressing SFFV-Cas9-BFP were infected with the aforementioned genomewide sgRNA library at an MOI < 1. Infected cells underwent puromycin selection (1 μ g/ml) for 5 d, puromycin was then removed, and cells were resuspended in normal growth medium without puromycin. After selection, sgRNA infection was measured by flow cytometry, which confirmed that > 90% of cells were mCherry + . Sufficient sgRNA library representation was confirmed by deep sequencing after selection. Cells were maintained for 3 weeks at 1,000× coverage (~1,000 cells containing each sgRNA) at a concentration of 500,000 cells/ml for the duration of each screen. Cells were split into two conditions: one control group that remained untreated and one group that was treated with the respective synthetic DPR (PR 20 at 8 µ M or GR 20 at 10 µ M). This treatment occurred four times over three weeks, and cells recovered to ~90% viability after each round of treatment. At the end of each screen, genomic DNA was extracted for all screen populations separately according to the protocol included with the Qiagen Blood Maxi Kit, and deep sequencing on an Illumina Nextseq platform was used to monitor library composition. Guide composition between PR-or GR-treated conditions was compared with the untreated condition by using casTLE 45 version 1.0 (URLs). Briefly, the enrichment of individual guides was calculated as the log ratios between treated and untreated conditions, and gene-level effects were calculated from ten guides targeting each gene. A confidence score was then derived as a loglikelihood ratio describing the significance of the gene-level effect. P values were then calculated by permutating the targeting guides as previously described 45 .
K562 competitive-growth assays. K562 cells stably expressing Cas9 were infected with sgRNAs targeting each gene of interest for validation from the genomewide screen. sgRNA plasmids also encoded GFP. Cells were selected for stable sgRNA expression with puromycin (1 µ g/ml) and were confirmed to be GFP positive before use in competitive-growth assays. Equal numbers of GFP + /sgRNAexpressing cells were cocultured with WT/GFPcells and were subsequently treated with 10 μ M PR 20 . The percentage of GFP + cells was quantified by fluorescenceactivated cell sorting with a BD Accuri C6 flow cytometer after 48 h.
Pretreatment of ISRIB in PR 20 -exposed K562s. ISRIB (Sigma SML0843) was dissolved in DMSO and added to the K562 cell line at a concentration of 15 nM 3 h before treatment with PR 20 . An equal amount of DMSO was added to cells that were not pretreated with ISRIB. 15 µ M of PR 20 was then added to these cells, and a third group of K562s were not treated with ISRIB or PR 20 and served as an untreated control. 24 h after PR 20 treatment, cells were measured with a BD Accuri C6 flow cytometer for forward-and side-scatter analysis. All experiments were performed in triplicate.
CRISPR-Cas9 screen for DPR toxicity in primary mouse cortical neurons.
Cortical tissue from mouse E.16.5 embryos (Gt(ROSA)26Sor tm1.1(CAG-Cas9*,-EGFP)Fezh /J; Jackson Laboratory stock no: 024858) was dissected and dissociated into a singlecell suspension with a papain dissociation system (Worthington Biochemical Corporation). 7 million cells were seeded onto 10-cm dishes in Neurobasal medium (Gibco) supplemented with B-27 serum-free supplement (Gibco), GlutaMAX (Gibco), and penicillin-streptomycin (Gibco). Half the culture medium was replenished every 4 or 5 d. One day after seeding, neurons were infected with a lentiviral library containing ~3,000 sgRNA elements consisting of 178 genes (5% FDR for PR 20 genome-wide-screen hits), ten sgRNAs per gene, and 1,000 negativecontrol sgRNAs, synthesized and cloned as previously described 45 . Transductions were performed with a titer resulting in a 50-70% infection rate. Cas9-mediated genome editing was allowed to occur for 2 weeks in culture, after which PR 20 synthetic dipeptides or PR 50 -expression lentivirus particles were applied.
Synthetic DPR screen. Half the cells were left untreated (control group), and the other half were treated with 1.5 μ M synthetic PR 20 for 24 h, thus resulting in approximately 90% cell death.
Lentivirus-mediated DPR screen. Half the cells were infected with control lentivirus particles for expression of eGFP from the synapsin promoter (control group), and the other half were infected with a lentivirus for expression of codon-optimized PR 50 from the synapsin promoter. Lentiviral PR 50 resulted in approximately 90% cell death between 4 and 6 d. To harvest DNA from the remaining live cells, cultures were washed three times in PBS, treated with DNase I (Worthington Biochemical Corporation) for 10 min at 37 °C (to remove any extracellular gDNA from dead neurons), then washed again three times in PBS to remove residual DNase I. Genomic DNA was harvested with a DNeasy Blood and Tissue Kit (Qiagen) including proteinase K digestion to inactivate residual DNase I. sgRNA amplification and library preparation for deep sequencing was performed as described above. Gene-level effects and confidence scores were calculated as in the primary screen. The significance of the gene-level effects was determined on the basis of the 95% credible intervals calculated in casTLE 45 . A gene was considered a hit if its 95% credible interval did not contain zero.
RNA sequencing. Total RNA quality control was performed with a Eukaryote Total RNA Nano assay on an Agilent 2100 Bioanalyzer System for all RNA samples before library preparation for RNA sequencing. mRNA libraries were prepared for Illumina paired-end sequencing with an Agilent SureSelect Strand Specific RNA-Seq Library Preparation kit on an Agilent Bravo Automated Liquid Handling Platform. Libraries were sequenced on an Illumina NextSeq sequencer. Alignment of RNA-sequencing reads to the transcriptome was performed with STAR with ENCODE standard options, read counts were generated with rsem, and differential expression analysis was performed in R with the DESeq2 package 80 . All bioinformatics analyses were performed on Sherlock, a Stanford HPC cluster.
qRT-PCR. cDNA was reverse transcribed from total RNA samples with a High Capacity cDNA Reverse Transcription Kit (ThermoFisher Scientific). TaqMan assays (Applied Biosystems) for ATF3, ATF4, ATF5, CHAC1, DDIT3, BBC3, and BAX were used in qPCR reactions with inventoried TaqMan Universal PCR Master Mix (ThermoFisher Scientific) and a StepOne or QuantStudio 3 real-time PCR machine. To measure XBP1 splicing, cDNA was generated as described above, and equal amounts of cDNA (2 μ l) were used in a PCR with KOD polymerase (EMD Millipore 71086). Primers used in these experiments are listed in Supplementary Western blotting. Protein lysates were prepared with RIPA buffer supplemented with 1× Halt Protease Inhibitor Cocktail (Pierce). Crude lysates were centrifuged at 12,500 g for 10 min at 4 °C to remove cellular debris. Clarified lysates were quantified with a Pierce BCA protein assay. Equal amounts of protein were subjected to SDS-PAGE, transferred to nitrocellulose membranes, and immunoblotted according to standard protocols. The following antibodies were used: mouse anti-GAPDH (1:5,000, clone GAPDH-71.1, Sigma G8795), rabbit polyclonal anti-TMX2 (1:1,000, Novus NBP1-87305), and rabbit polyclonal anti-XPO5 (1:2,000, Bethyl Laboratories A303-991A).
Cytotoxicity assay. K562 cell viability after DPR treatment was measured by flow cytometry with a BD Accuri C6 flow cytometer by measuring the number of events in forward-scatter and side-scatter gates. Cytotoxicity in primaryneuron cultures was measured by LDH release assays (Promega, CytoTox 96 Non-Radioactive Cytotoxicity Assay) and by NeuN + quantification of surviving neurons with immunocytochemistry. To quantify the numbers of NeuN + neurons, cells were fixed and stained as described above and quantified with ImageJ. Briefly, thresholds were applied to image stacks to detect NeuN + neuronal nuclei, which were then automatically counted with built-in ImageJ plugins. Additional cytotoxicity assays were performed with the Caspase-Glo 3/7 Assay (Promega G8090), a luminescence-based readout of caspase 3/7 activity (DEVDase activity) in neurons, according to the manufacturer's instructions.
Virus production for induced motor neuron experiments. cDNAs for iMN factors (Ngn2, Lhx3, Isl1, NeuroD1, Ascl1, Myt1l, and Brn2) were purchased from Addgene. Each cDNA was cloned into the pMXs retroviral expression vector with Gateway cloning technology (Invitrogen). The Hb9::RFP lentiviral vector was also purchased from Addgene (ID 37081). Viruses were produced as follows: HEK293 cells were transfected at 80-90% confluency with viral vectors containing genes of interest and viral packaging plasmids (PIK-MLV-gp and pHDM for retrovirus; pPAX2 and VSVG for lentivirus) with PEI (Sigma-Aldrich). The medium was changed 24 h after transfection. Viruses were harvested at 48 h and 72 h after transfection. Viral supernatants were filtered with 0.45-μ M filters, incubated with Lenti-X concentrator (Clontech) for 24 h at 4 °C, and centrifuged at 1,500 g at 4 °C for 45 min. The pellets were resuspended in 300 μ l DMEM with 10% FBS and stored at -80 °C.
Generation of Dox-NIL induced motor neurons. To generate Dox-NIL iMNs, the Dox-NIL construct was integrated into the AAVS1 safe-harbor locus of the control and C9-ALS patient iPSC lines with CRISPR-Cas9 editing (gRNA sequence in Supplementary Table 4 ). The conversion of NIL-iMNs was performed in 96-well plates (2 × 10 3 cells/well), which were sequentially coated with Matrigel (1 h) and laminin (2-4 h) at room temperature. iPSCs were cultured in mTeSr and induced with 1 μ g/ml doxycycline on day 1 after plating. On day 3 after plating, the culture was transduced with control shRNA1, control shRNA2, TMX2 shRNA1, and TMX2 shRNA2 with 5 μ g/ml polybrene in N3 medium containing DMEM/F12 (Life Technologies), 2% FBS, 1% penicillin/streptomycin, N2 and B27 supplements (Life Technologies), and 10 ng/ml each of GDNF, BDNF, and CNTF (R&D). For the detection of the motor neurons, the culture was transduced with Hb9::RFP reporter 48 h after shRNA transduction. On day 5, primary mouse cortical glial cells from P1 ICR pups (male and female) were added to the transduced cultures in N3 medium.
Generation of 7F induced motor neurons. Reprogramming was performed in 96-well plates (8 × 10 3 cells/well) that were sequentially coated with gelatin (0.1%, 1 h) and laminin (2-4 h) at room temperature. To enable efficient expression of the transgenic reprogramming factors, iPSCs were cultured in fibroblast medium (DMEM with 10% FBS) for at least 48 h and were either used directly for retroviral transduction or passaged before transduction for each experiment. Seven iMN factors were added in 100-200 μ l fibroblast medium per well in 96-well plates with 5 μ g/ml polybrene. For iMNs, cultures were transduced with lentivirus encoding the Hb9::RFP reporter 48 h after transduction with transcription-factorencoding retroviruses. On day 5, primary mouse cortical glial cells from P1 ICR pups (male and female) were added to the transduced cultures in glia medium containing MEM (Life Technologies), 10% donor equine serum (HyClone), 20% glucose (Sigma-Aldrich), and 1% penicillin-streptomycin. On day 6, cultures were switched to N3 medium containing DMEM/F12 (Life Technologies), 2% FBS, 1% penicillin/streptomycin, N2 and B27 supplements (Life Technologies), 7.5 μ M RepSox (Selleck), and 10 ng/ml each of GDNF, BDNF, and CNTF (R&D). The iMN neuron cultures were maintained in N3 medium, which was changed every other day, unless otherwise noted.
Induced motor neuron survival assay. Hb9::RFP + neurons appeared between days 10 and 13 after initial seeding. Doxycycline was withdrawn at day 10, and the survival assay was initiated at day 20. For the glutamate treatment, 10 μ M glutamate was added to the culture medium on day 20 and removed after 24 h. Longitudinal tracking was performed by imaging neuronal cultures in a Nikon Biostation CT instrument once every 24 h starting at day 20. Tracking of neuronal survival was performed with SVcell 3.0 (DRVision Technologies). Neurons were scored as dead when their soma was no longer detectable on the basis of RFP and GFP fluorescence. All neuron survival assays were performed at least twice, and one of the trials was used for the quantification shown. All trials quantified were representative of other trials of the same experiment. For iMNs from multiple independent donors that were combined into one survival trace in the Kaplan-Meier plots for clarity, the number of iMNs tracked from each line can be found in Supplementary Table 4 .
Statistics.
Statistical tests were performed with GraphPad Prism 7. Two-tailed t tests, one-way ANOVAs, or log-rank tests for survival curves were used as indicated.
Life Sciences Reporting Summary. Further information on experimental design is available in the Life Sciences Reporting Summary.
Data availability. RNA-sequencing data from this study have been deposited in the NCBI GEO database under accession number GSE109177 The data supporting the findings of this study are available from the corresponding author upon reasonable request.
